Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 December 2008, Vol. 112, No. 12, pp. 4361-4362.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izraeli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izraeli, S.
Related Collections
Right arrowRelated Articles in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Next Article next article arrow

InsideBlood

HEMATOPOIESIS & STEM CELLS

Comment on Chou et al, page 4503, andTunstall-Pedoe et al, page 4507

Trisomy 21 tilts the balance

Shai Izraeli

SHEBA MEDICAL CENTER

By studying hematopoiesis in human FLs, 2 independent studies by Tunstall-Pedoe et al and Chou and colleagues have identified important clues to explain the high incidence of megakaryocytic leukemias in infants with DS.

Approximately 5% of children with Down syndrome (DS) are born with a unique transient clonal megakariyo-erythroblastic proliferation disorder often called transient myeloproliferative disorder (TMD). Spontaneous recovery usually occurs within up to several months. However, about one-fifth of these patients will develop full-blown acute leukemia with biphenotypic megakaryocytic-erythroid features (AMKL) during their first 4 years of life. Somatic mutations in the transcription factor GATA1 are present in most patients with DS-TMD and AMKL.13 These mutations invariably result in the expression of a shorter isoform, GATA1s. The expression of this isoform is thought to enhance the proliferation and reduce the differentiation of fetal liver (FL) megakaryoblastic progenitors.4 How cT21 synergizes with mutated GATA1 in initiation of this common and generally reversible congenital clonal hematopoietic proliferation syndrome has been a mystery.

We have previously proposed a model to explain this collaboration between cT21 and GATA1s, as shown in the figure.5 We suggested that increased expression of several human chromosome 21 (Hsa21) genes in FL hematopoietic progenitor cells (HPCs) that normally regulate megakaryopoiesis (eg, ERG, ETS-2, RUNX1, BACH-1, and others) tilts the balance of fetal hematopoeisis toward the megakaryocytic lineage. Similar to a traffic accident during morning rush hour, an acquired mutation in GATA1 blocks further differentiation and induces a clonal "pile-up" of megakaryocytic precursors manifested at birth as TMD. This model predicts the presence of markedly enhanced megakaryopoiesis preceding the occurrence of GATA1s mutation in human livers from DS fetuses.


Figure 1
View larger version (80K):
[in this window]
[in a new window]

 
Proposed model for the mechanism for the leukemogenic cooperation between constitutional trisomy 21 (cT21) and GATA1s mutations in the megakaryoblastic leukemias of DS.5 Increased expression of genes from cT21 in fetal liver HPCs tilt the normal hematopoiesis toward increased production of megakaryocytic erythroid progenitors (MEPs). It's also possible that cT21 blocks terminal megakaryocytic (MK) differentiation. The somatically-acquired GATA1s mutation further blocks MK differentiation and enhances the proliferation of the MEPs. Professional illustration by Alice Y. Chen.

 
The 2 new studies by Tunstall-Pedoe et al and Chou and colleagues confirm that prediction. They compared second-trimester FL hematopoiesis in DS without GATA1 mutations to gestation-matched healthy controls. Strikingly, more than half of the HPCs in DS FLs were megakaryocyte-erythroid progenitors, 3 times more than in disomic FLs. In addition to the developmental shift toward the megakaryocytic-erythroid lineage, there was marked increase in proliferation and self-renewal of these progenitors.

Tunstall-Pedoe et al have also found that all these abnormalities were absent in bone marrows (BMs) of DS fetuses (although no BMs from older fetuses were analyzed). These observations are consistent with the clinical syndrome of TMD, which often involves the liver but not the bone marrow. The specific association with FL hematopoiesis could have been explained by either unique properties of the DS FL microenvironment or by a cell autonomous effect of cT21 on FL HPCs. Repopulation experiments performed by Chou et al in immunodeficient mice with hematopoietic cells from DS and control FLs suggest that the tilt toward the megakaryoblastic-erythroid lineage is a cell autonomous property endowed to the FL HPC by cT21. Since Chou et al have not studied BM cells, the specific association with FL progenitors needs additional confirmation. However, together these studies are intriguing because of previous research in a knock-in mouse model that demonstrated that the GATA1s isoform enhanced proliferation of early FL HPCs while having no effect on postnatal BM cells.4 It is therefore tempting to speculate that cT21 causes an increased proliferation and megakaryocytic-erythroid differentiation of a unique FL HPC that is sensitive to the GATA1s mutation.

The fascinating observations of human FL hematopoiesis in DS raise at least 2 interesting questions: The first is what are the characteristics of FL HPCs that are sensitive to cT21 and the GATA1s mutation? Indeed little is known on what distinguishes hematopoietic development in FL compared with the fetal BM. The second is which Hsa21 gene or genes contribute to the remarkable effects of cT21 on FL hematopoiesis? As multiple genes are expressed from trisomic chromosomes,6 it is possible that cooperation among several Hsa21's is responsible for cT21 effects, as has also been suggested for explanation of other phenotypes of DS.7

Similarly to the leukemias of DS, sporadic childhood leukemias are initiated in utero. Somatic structural or numerical chromosomal aberrations acquired in fetal hematopoietic progenitors initiate the growth of a preleukemic clone.8 Thus, the relevance of studies, such as the 2 reported by Tunstall-Pedoe and Chou and their colleagues, extends beyond DS. They are important for the general understanding of how normal fetal hematopoietic development is diverted toward leukemia.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981–986.[Abstract/Free Full Text]

  2. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–152.[CrossRef][Medline] [Order article via Infotrieve]

  3. Taub JW, Mundschau G, Ge Y, et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004;104:1588–1589.[Free Full Text]

  4. Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–619.[CrossRef][Medline] [Order article via Infotrieve]

  5. Rainis L, Toki T, Pimanda JE, et al. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res. 2005;65:7596–7602.[Abstract/Free Full Text]

  6. Hertzberg L, Betts DR, Raimondi SC, et al. Prediction of chromosomal aneuploidy from gene expression data. Genes Chromosomes Cancer. 2007;46:75–86.[CrossRef][Medline] [Order article via Infotrieve]

  7. Roper RJ, Reeves RH. Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006;2:e50.[CrossRef][Medline] [Order article via Infotrieve]

  8. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3:639–649.[CrossRef][Medline] [Order article via Infotrieve]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Articles in Blood Online:

Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations
Oliver Tunstall-Pedoe, Anindita Roy, Anastasios Karadimitris, Josu de la Fuente, Nicholas M. Fisk, Phillip Bennett, Alice Norton, Paresh Vyas, and Irene Roberts
Blood 2008 112: 4507-4511. [Abstract] [Full Text] [PDF]

Trisomy 21 enhances human fetal erythro-megakaryocytic development
Stella T. Chou, Joanna B. Opalinska, Yu Yao, Myriam A. Fernandes, Anna Kalota, John S. J. Brooks, John K. Choi, Alan M. Gewirtz, Gwenn-ael Danet-Desnoyers, Richard L. Nemiroff, and Mitchell J. Weiss
Blood 2008 112: 4503-4506. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Hum Mol GenetHome page
I. Ganmore, G. Smooha, and S. Izraeli
Constitutional aneuploidy and cancer predisposition
Hum. Mol. Genet., April 15, 2009; 18(R1): R84 - R93.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Izraeli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izraeli, S.
Related Collections
Right arrowRelated Articles in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020